Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy
Top Cited Papers
- 1 July 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (13) , 3942-3950
- https://doi.org/10.1158/1078-0432.ccr-07-0278
Abstract
Purpose: Dysfunctional tumor vessels can be a significant barrier to effective cancer therapy. However, increasing evidence suggests that vascular endothelial growth factor (VEGF) inhibition can effect transient “normalization” of the tumor vasculature, thereby improving tumor perfusion and, consequently, delivery of systemic chemotherapy. We sought to examine temporal changes in tumor vascular function in response to the anti-VEGF antibody, bevacizumab.Keywords
This publication has 35 references indexed in Scilit:
- Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: Importance of optimal scheduling to exploit the ‘normalization’ window of the tumor vasculatureCancer Letters, 2006
- Interferon-mediated anti-angiogenic therapy for neuroblastomaCancer Letters, 2005
- Improving delivery of antineoplastic agents with anti‐vascular endothelial growth factor therapyCancer, 2005
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiationRole of oxygenation, angiopoietin-1, and matrix metalloproteinasesCancer Cell, 2004
- Restriction of neuroblastoma angiogenesis and growth by interferon-α/βSurgery, 2004
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor modelBlood, 2002